The Oregon Prescription Drug Affordability Board is currently reviewing the affordability of 27 selected medications and has requested feedback from individuals and organizations to inform its assessments. In response, Aimed Alliance submitted a comment urging the Board to adopt a deliberate, evidence-based approach to its evaluations and decision-making. The letter emphasized the importance of meaningfully incorporating and reconciling patient-reported feedback, concerns, and data in the Board’s final affordability determinations to ensure its actions effectively address the needs of patients across Oregon. Read the comment here.
Last Updated on May 3, 2025 by Aimed Alliance
